Briefing

The compounding rules

Cheap GLP-1s exist because of compounding. The FDA moved against it again in April. What that means for the board.

Updated 2026-09-18

DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.

Every price at the cheap end of our board depends on compounding remaining legal in something like its current form. In 2026 that is no longer a safe assumption.

Compounded GLP-1s are no longer the freely marketed product they were in 2024. They remain legal in a narrower form, and the rules changed again in 2026.

The timeline

When	What happened
December 2024	FDA declared the tirzepatide shortage resolved.
February 2025	FDA declared the semaglutide shortage resolved, ending the shortage-based pathway that allowed large-scale compounding.
16 September 2025	FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications.
1 April 2026	FDA reminded compounders that specific conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B.
30 April 2026	FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, saying there is no clinical need for compounded versions.
30 July 2026	Comment period on that proposal closed after an extension.
December 2025	FDA approved the first oral GLP-1 for weight management, the Wegovy pill, which launched in the US on 5 January 2026 from $149/month.
1 April 2026	FDA approved Foundayo (orforglipron), the first oral small-molecule GLP-1 for weight management, with self-pay from $149/month.
6 May 2026	CMS announced the Medicare GLP-1 Bridge, giving eligible Part D beneficiaries certain GLP-1s for $50 a month from 1 July 2026 through 31 December 2027.

What it means now

A 503A pharmacy may still compound a GLP-1 for an individual patient when there is a documented, patient-specific clinical reason — for example a required dose or formulation that the approved product does not provide.
Routinely marketed, off-the-shelf compounded GLP-1 sold like a consumer product is not permitted under that framework.
If the 503B Bulks List proposal is finalised, outsourcing facilities would lose the pathway they have been using to produce these drugs in volume.
Compounded versions are not FDA-approved. The agency does not review them for safety, effectiveness or manufacturing quality the way it reviews Zepbound or Wegovy.
The price argument for compounding is much weaker than it was. Two FDA-approved oral GLP-1s now start at $149 a month, and eligible Medicare beneficiaries can access certain GLP-1s for $50 a month from July 2026 — both below what many compounded programmes charge.

Read this bit. This matters most if you are considering an annual plan. Ask what happens to your remaining prepaid months if the supply route closes — and get the answer in writing before you pay, not after.

What it would do to the board

If the 503B Bulks List proposal is finalised, outsourcing facilities lose the pathway they have used to produce these drugs at volume. 503A pharmacies could still compound for individual patients with a documented clinical reason — but routinely marketed compounded GLP-1 would not survive it. The cheap end of this board is built on exactly that.

Five questions for any programme

Which pharmacy fills this, and is it 503A or 503B?
What is the patient-specific clinical reason for compounding in my case?
What happens to my prescription and my prepaid months if the rules change?
Can you move me to an FDA-approved product without restarting, and at what price?
Is my quoted figure the ongoing price or an introductory one?

The programmes this does not affect

Ro works only with approved medication. Mochi and LifeMD will pursue insurance coverage for branded prescriptions. Through LillyDirect self-pay, single-dose Zepbound vials at 5 mg, 7.5 mg and 10 mg have been listed at $499/month, with lower starting doses nearer $299-$349. Through NovoCare, Wegovy has been offered at $199/month for the first two fills through 31 December 2026, then $349/month for 0.25-2.4 mg doses. The oral form is listed between $149 and $299/month by dose.